Skip to main content
♕ The Globe and Mail Trade Off
Canada's free stock market contest is live! Test your investing skills for a chance to win $5,000.Enter Now!Enter Now!
➜

Medexus Pharmaceuticals Inc(MDP-T)
TSX

Today's Change
Real-Time Last Update
Day Low3.10
Day High3.16
Open:3.16
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Medexus Pharmaceuticals Inc

Select a category then submit the form to load news
Newsfile
Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Newsfile
Medexus Schedules Third Fiscal Quarter 2026 Conference Call
Newsfile
Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares
Newsfile
Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares
Newsfile
Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Newsfile
Medexus Schedules Second Fiscal Quarter 2026 Conference Call
Newsfile
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Newsfile
Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection
Newsfile
Medexus Schedules First Fiscal Quarter 2026 Conference Call
Newsfile
GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS's Fiscal Year 2026
Newsfile
Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States
Newsfile
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call
Baystreet
Stocks in play: Medexus Pharmaceuticals
Newsfile
Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada
Baystreet
Stocks in play: Medexus Pharmaceuticals
Newsfile
Medexus Provides Update on Progress of Commercialization of GRAFAPEX (treosulfan) for Injection
Baystreet
Stocks in play: Medexus Pharmaceuticals
Newsfile
Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp.
AI-generated - The Globe and Mail
Medexus Pharma: Top 10 Undervalued Healthcare Sector Stocks on TSX (MDP)
Newsfile
Medexus Announces Commercial Availability of GRAFAPEX (treosulfan) for Injection
Baystreet
Stocks in play: Medexus Pharmaceuticals
AI-generated - The Globe and Mail
Medexus Pharma: Top 10 Undervalued Drug Manufacturers Industry Stocks (MDP)
The Globe and Mail
Where this Canadian micro-cap manager is finding shelter from the broader market
illustration of Alexander Etsell for The Mover. July 23, 2022 Illustration by Joel Kimmel
PR Newswire
Canadian Investment Regulatory Organization Trade Resumption - MDP
Newsfile
Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States
Baystreet
Stocks in play: Medexus Pharmaceuticals
Newsfile
Medexus and Ontario's Provincial Health Services Successfully Complete Agreements for Public Reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada
Newsfile
Medexus Schedules Third Fiscal Quarter 2025 Conference Call
Newsfile
Medexus Pharmaceuticals Announces Closing of $30 Million Overnight Marketed Public Offering of Common Shares
GlobeNewswire
Medexus Pharmaceuticals Announces Overnight Marketed Public Offering of Common Shares
PR Newswire
Canadian Investment Regulatory Organization Trading Halt - MDP
The Globe and Mail
Thursday’s analyst upgrades and downgrades
Storage silos are shown in Niantic, Ill. in a Thursday, Oct. 23, 2014 file photo

Profile

Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.